Множественная миелома: диагностика и терапия (часть 1)

Множественная миелома: диагностика и терапия (часть 1)

Автор: Бессмельцев С.С.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Передовая статья

Статья в выпуске: 2 т.18, 2022 года.

Бесплатный доступ

Множественная миелома (ММ) - это гетерогенное заболевание, определяемое клональной пролиферацией плазматических клеток, гематологическая опухоль, которая составляет 1,0-1,8% среди всех видов онкологических заболеваний. Первоначальная диагностика включает необходимые базовые лабораторные исследования: исследование периферического мазка крови, креатинин в сыворотке крови, клиренс креатинина, сывороточный кальций, альбумин, лактатдегидрогеназа и бета-2 микроглобулин. Исследование костного мозга на начальном этапе должно включать анализ хромосом методом флуоресцентной гибридизации in situ (FISH), выполняемый на плазматических клетках, полученных при аспирации костного мозга. В последние десятилетия в результате широкого применения аутологичной трансплантации гемопоэтических стволовых клеток (аутоТГСК) и новых, весьма эффективных лекарственных средств, существенно улучшились показатели выживаемости пациентов с множественной миеломой. Для пациентов

Еще

Множественная миелома, бортезомиб, леналидомид, моноклональные антитела, полная ремиссия, общая выживаемость, аутологичная трансплантация гемопоэтических стволовых клеток

Короткий адрес: https://sciup.org/170195750

ID: 170195750

Список литературы Множественная миелома: диагностика и терапия (часть 1)

  • Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: рук. для врачей. - М.: МК. 2016. - 504.
  • Moreau P., San Miguel J., Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.// Ann Oncol. - 2017. - Vol. 28, Suppl 4. - P. iv52-61.
  • SEER Cancer Stat Facts: Myeloma. Bethesda: National Cancer Institute. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 24 Feb 2020.
  • Fonseca R., Usmani S.Z., Mehra M. et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. - BMC Cancer. - 2020. - Vol. 20. - P. 1087-1098.
  • Kumar S.K., Callander N.S., Alsina M. et al. NCCN guidelines insights: multiple myeloma, version 3.2018.// J Natl Compr Canc Netw. - 2018. - Vol. 16. - P. 11-20.
  • Moreau P, Rajkumar SV. Multiple myeloma—translation of trial results into reality. // Lancet. - 2016. - Vol. 388. - P. 111-113.
  • Usmani S.Z., Hoering A., Cavo M. et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project.// Blood Cancer J. - 2018. - Vol. 8. - P. 123.
  • Бессмельцев С.С. Множественная миелома (лечение первичных больных): обзор литературы и собственные данные. Часть 11//Клиническая Онкогематология. - 2013. - №4. - С. 379-414.
  • Fonseca R., Blood E., Rue M. et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma// Blood. -2003. - Vol. 101, N 11. - P. 4569-4575
  • Moreau P. How I treat myeloma with new agents.// Blood. - 2017. - Vol. 130. - P. 1507-1513.
  • Richardson P.G., San Miguel JF., Moreau P. et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.// Blood Cancer J. - 2018. - Vol. 8. - P. 109.
  • Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. - Алматы: Коста, 2007. - 480 с.
  • Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma// Lancet Oncol. - 2014. - Vol. 15, N12. - P. e538-e548.
  • Greipp P. R., San Miguel J., Durie B. G.M. et al. International Staging System for Multiple Myeloma// J Clin Oncol. - 2005. - Vol. 23. - P. 3412-3420.
  • Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma// Leukemia. - 2009. - Vol. 23. P. 3-9.
  • Avet-Loiseau H., Attal M., Moreau P. et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome// Blood. - 2007. - Vol. 109. - P. 3489-3495.
  • Boyle E.M., Walker B.A., Wardell C.P. et al. Mutational patterns and copy number changes at diagnosis are a powerful tool to predict outcome: result of the sequencing study of 463 newly diagnosed myeloma trial patients. Presented at: 2014 Annual Meeting of the ASCO; San Francisco, 2014, Asbstr. 637.
  • Dimopoulos M., Terpos E., Comenzo R.L. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma// Leukemia advance online publication, 7 May 2009;doi:10.1038/leu. - 2009. - P. 1-12.
  • Sawyer J., Shaughnessy J. D., Haussler J. et al. Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk// J Clin Oncol. - 2010. - Vol. 28. - P. 15s (suppl; abstr 8122).
  • Dispenzieri A., Rajkumar S. V., Gertz M.A. et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement.//Mayo Clin Proc// 2007. - Vol. 82. - P. 323-341;
  • Kumar S.K., Mikhael J. R., Buadi F.K. et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.//Mayo Clin Proc// 2009. - Vol. 84. - P. 1095-1110.
  • Nandakumar B., Binder M., Dispenzieri A. et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients.// J Clin Oncol. - 2019. - Vol. 37, Abstr. 8039. Rajkumar S. V., Kumar Sh. Multiple myeloma current treatment algorithms//Blood Cancer J. - 2020. - Vol. 10, N 9. - P. 94.
  • Kumar S., Paiva B., Anderson K.C. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.// Lancet Oncol. - 2016. - Vol. 17. - P. e328-e346).
  • Perrot A., Lauwers-Cances V., Corre J. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.// Blood. - 2018. - Vol. 132. - P. 2456-2464.
  • Munshi N.C., Avet-Loiseau H., Rawstron A.C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis.// JAMA Oncol.- 2017. - Vol. 3. - P. 28-35.
  • Cavo M., Terpos E., Nanni C. et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.// Lancet Oncol. - 2017. - Vol. 18. - P. e206-e217.
  • Avet-Loiseau H., Ludwig H., Landgren O. et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis.// Clin Lymphoma Myeloma Leuk. - 2020. - Vol. 20. - P. :e30-e37.
  • Dimopoulos M. A., Moreau P., Terpo E. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up// Annals Oncology. - 2021. - Vol. 32. - P. 309-322.
  • Shaji K. Kumar, Natalie S. et al. Multiple Myeloma, Version 3.2021. NCCN Clinical Practice Guidelines in Oncology.// J Natl Compr Canc Netw . - 2020. - Vol. 18, N 12. - P. 1685-1717.
  • Attal M., Lauwers-Cances V., Hulin C. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.// N Engl J Med. - 2017. - Vol. 76. - P. 1311-1320.
  • Cavo M., Gay F., Patriarca F. et al. Double autologous stem cell trans- plantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study.// Blood. - 2017. - Vol. 130, Suppl 1. - P. 401.
  • Cavo M., Gay F., Beksac M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.// Lancet Haematol. - 2020. - Vol. 7. - P. e456-e468.
  • Hari P., Pasquini M., Stadtmauer E. et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).// J Clin Oncol. - 2020. - Vol. 38, Suppl 15. - P. 8506.
  • Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.// J Clin Oncol. - 2007. - Vol. 25, N 17. - P. 2434-2441.
  • Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.// Blood. - 2012. - Vol. 119. - P. 4375-4382.
  • Mai E.K., Bertsch U., Durig J. et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.// Leukemia. - 2015. - Vol. 29. - P. 1721-1729.
  • Кострома И.И., Жернякова А.А., Запреева И.М., Сидорова Ж.Ю., Семенова Н.Ю., Карягина Е.В., Степченкова Е.И., Бессмельцев С.С., Чечеткин А.В., Грицаев С.В. Ретроспективный анализ выживаемости больных множественной миеломой после трансплантации аутологичных стволовых клеток// Клиническая онкогематология. - 2021. - Т. 14, №1. - С. 73-79.
  • Gay F., Cerrato C., Petrucci M. et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial.// J Clin Oncol. - 2019. - Vol. 37, Suppl 15. - P. 8002.
  • Gay F., Musto P., Rota-Scalabrini D. et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial// Lancet Oncol. - 2021. - Vol. 22. - P. 1705-1720.
  • Rajkumar S.V. Myeloma today: Disease definitions and treatment advances.// Am J Hematol. - 2016. - Vol. 91, N 1. - P. 90-100. Бессмельцев С.С. Анти-CD38 моноклональные антитела в лечении рецидивов/рефрактерных форм множественной миеломы.// Вестник гематологии. -2018. - Т. XIV, № 3. - C. 5-18.
  • Deckert J., Wetzel M.C., Bartle L.M. et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 hematologic malignancies.// Clin Cancer Res. - 2014. - Vol. 20, N17. - P. 4574-4583.
  • van de Donk W.C.J., Richardson P., Malavasi F. CD38 antibodies in multiple myeloma: back to the future.//Blood. - 2018. - Vol. 131, N1. - P. 13-29.
  • Moreau P., Attal M., Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.// Lancet. - 2019. - Vol. 394. - P. 29-38.
  • Voorhees P.M., Kaufman J.L., Laubach J. et al. Daratumumab, lenalido- mide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.// Blood. - 2020. - Vol. 136. - P. 936-945.
  • Costa L.J., Chhabra S., Medvedova E. et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma// Journal of Clinical Oncology. - Published online December 13, 2021.DOI: 10.1200/JCO.21.01935.
  • Kumar S.K., Callander N.S., Adekola K. et al. NCCN Clinical practice guidelines in oncology. Multiple Myeloma, Version 3.2021. Bruno B., Rotta M., Patriarca F. et al. A comparison of allografting with autografting for newly diagnosed myeloma// N Engl J Med. - 2007. - Vol. 356. - P. 1110-1120.
  • Bjorkstrand B., Lacobelli S., Hegenbart A. Autologous stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: a prospective controlled trial by the EBMT// Bone Marrow Transplant. - 2009. - Vol. 43. - P. 223 (Abstr.).
  • Garban F., Attal M., Michallet M. et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma// Blood. - 2006. - Vol. 107. - P. 3477-3480.
  • Lokhorst H., Sonneveld P., van der Holt B. et al. Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/50 Study// Blood. - 2008. - Vol. 112. - P. 461 (Abstr.).
  • Rosinol L., Perez-Simin J.A., Sureda A. et al. A prospective PETEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma// Blood. - 2008. - Vol. 112. - P. 3591-3593.
  • Giralt S., Costa L.J., Maloney D. et al. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.// Biol Blood Marrow Transplant. - 2020. - Vol. 26. - P. 798-804.
  • Fermand J. P., Ravaud P., Chevret S. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.// Blood. - 1998. - Vol. 92, N 9. - P. 3131-3136.
  • Barlogie B., Kyle R.A., Anderson K.C. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. //J. Clin. Oncol. - 2006. - Vol. 24, N 6. - P. 929-936.
  • Attal M., Lauwers-Cances V., Hulin C. et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). // Blood. - 2015. - Vol. 126. - P. 391.
  • Karam D., Gertz M., Lacy M.et al. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant// Bone Marrow Transplantation; https://doi.org/10.1038/s41409-022-01631-8.
  • Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG- HD4 trial. // J Clin Oncol. - 2012. - Vol. 30. - P. 2946-2955.
  • Dimopoulos M.A., Gay F., Schjesvold F. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial// Lancet. - 2019. - Vol. 393. - P. 253-264.
  • Ruth M. De Tute, Pawlyn C., Cairns D.A. et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients with Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk// J Clinical Oncology. Published in Oncology Journal Scan, April 19, 2022.
  • Durie B.G.M., Hoering A., Abidi M.H. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial.// Lancet. - 2017. - Vol. 389. - P. 519-527.
  • Kumar S.K., Jacobus S.J., Cohen A.D. et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.// Lancet Oncol. - 2020. - Vol. 21. - P. 1317-1330.
  • O'Donnell E.K., Laubach J.P., Yee A.J. et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma// Br J Haematol. - 2018. - Vol. 182. - P. 222-230.
  • Mateos M.V., Cavo M., Blade J. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.// Lancet. - 2020. - Vol. 395. - P. 132-141.
  • Facon T., Kumar S.K., Plesner T. et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomized, open-label, phase 3 trial. // Lancet Oncol. - 2021. - Vol. 22, N 11. - P. 1582-1596.
  • Facon T., Kumar S., Plesner T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.// N Engl J Med. - 2019. - Vol. 380. - P. 2104- 2115.
  • San-Miguel J., Avet-Loiseau H., Paiva B. et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE// Blood - 2020. - Vol. 136, Suppl.1. - P. 18-20.
  • Cao Y., Wan N., Liang Z. et al. Treatment outcomes in patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation: systematic review and network meta-analysis.// Clin Lymphoma Myeloma Leuk. - 2019. - Vol. 19. - P. e478-488.
  • Facon T., San-Miguel J, DimopoulosV.A. et al. Treatment Regimens for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta analysis//Adv Ther (2022). https://doi.org/10.1007/ s12325-022-02083-8.
Еще
Другой
SciUp 2024 © 2024 ©